Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 10/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 10/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CHRNA5 | P30532 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL225687 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL14003841 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29363551 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553851 | 0.98 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413921 | 0.98 | CHRNB4 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553574 | 0.87 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL22323984 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7143 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748444-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108466-A1 | VARENICLINE FORMULATIONS | PFIZER (US) | 2026-04-23 | — | — | US | claimed |
| US-20260102499-A1 | COMPOSITIONS WITH REDUCED NITROSAMINE IMPURITIES | INVENTIA HEALTHCARE LTD (IN) | 2026-04-16 | — | — | US | claimed |
| EP-4027815-B1 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | ACHIEVE LIFE SCIENCES INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719179-A2 | MANUFACTURING METHODS FOR GASTRIC RESIDENCE SYSTEMS | Nortiva Bio, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2026-04-07 | — | — | US | claimed |
| US-12576080-B2 | Use of varenicline for treating ocular conditions | Oyster Point Pharma, Inc. | 2026-03-17 | — | — | US | claimed |
| EP-4704838-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569498-B2 | Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2026-03-10 | — | — | US | claimed |
| JP-2006504654-A | — | — | 2006-02-09 | — | — | JP | claimed |
| US-20050281845-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-12-22 | — | — | US | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| CN-1668331-A | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-09-14 | — | — | CN | claimed |
| WO-2005063296-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| EP-1523334-A2 | HAPTEN-CARRIER CONJUGATES AND USES THEREOF | Cytos Biotechnology AG (CH) | 2005-04-20 | — | — | EP | claimed |
| WO-2004103372-A1 | PHARMACEUTICAL COMPOSITIONS OF VARENICLINE | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040235850-A1 | Pharmaceutical compositions of varenicline | PFIZER INC | 2004-11-25 | — | — | US | claimed |
| US-20040059094-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2004-03-25 | — | — | US | claimed |
| WO-2004009116-A2 | HAPTEN-CARRIER CONJUGATES COMPRISING VIRUS LIKE PARTICLES AND USES THEREOF | CYTOS BIOTECHNOLOGY AG (CH) | 2004-01-29 | — | — | WO | claimed |